Hannah T. Ryles

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe et al. · Cancer Cell · 2014 · 383 citations · Full text

Medicine, Receptor Tyrosine Kinase, Pathology +4

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Nicole R. Infarinato, Jin H. Park, Kateryna Krytska et al. · Cancer Discovery · 2015 · 180 citations · Full text

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

Kateryna Krytska, Hannah T. Ryles, Renata Sano et al. · Clinical Cancer Research · 2015 · 105 citations · Full text

Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma

Andrew Wood, Kateryna Krytska, Hannah T. Ryles et al. · Clinical Cancer Research · 2016 · 94 citations · Full text